Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target lowered by analysts at Wedbush from $38.00 to $36.00. They now have an "outperform" rating on the stock.
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates [Yahoo! Finance]
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results [Yahoo! Finance]